NI201800093A - Inhibidores de mcl1 macrocíclicos para tratar el cáncer - Google Patents
Inhibidores de mcl1 macrocíclicos para tratar el cáncerInfo
- Publication number
- NI201800093A NI201800093A NI201800093A NI201800093A NI201800093A NI 201800093 A NI201800093 A NI 201800093A NI 201800093 A NI201800093 A NI 201800093A NI 201800093 A NI201800093 A NI 201800093A NI 201800093 A NI201800093 A NI 201800093A
- Authority
- NI
- Nicaragua
- Prior art keywords
- macrocyclic
- treat cancer
- mcl1 inhibitors
- mcl1
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D497/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se da a conocer un compuesto que esácido 17-cloro-5,13,14,22-tetrametil-28-oxa-2,9-ditia-5,6,12,13,22-pentaazaheptacaciclo [27.7.1.14,7.011,15.016,21.020,24. 030,35] Octatriaconta-1(37), 4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaeno-23-carboxílico (fórmula I) y enantiómeros y sales farmacéuticamente aceptables del mismo. También se dan a conocer composiciones farmacéuticas de ácido 17-cloro-5,13,14,22-tetrametil-28-oxa-2,9-ditia-5,6,12,13,22- pentaazaheptacaciclo [27.7.1.14,7.011,15.016,21.020,24.030,35]Octatriaconta-1(37), 4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaeno-23-carboxílico, y enantiómeros y sales farmacéuticamente aceptables del mismo, y métodos de tratamiento del cáncer con tales compuestos y composiciones.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662326156P | 2016-04-22 | 2016-04-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NI201800093A true NI201800093A (es) | 2019-03-14 |
Family
ID=58664658
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NI201800093A NI201800093A (es) | 2016-04-22 | 2018-09-25 | Inhibidores de mcl1 macrocíclicos para tratar el cáncer |
Country Status (37)
| Country | Link |
|---|---|
| US (4) | US9840518B2 (es) |
| EP (1) | EP3445767B1 (es) |
| JP (1) | JP6894449B2 (es) |
| KR (1) | KR102388208B1 (es) |
| CN (1) | CN109071566B (es) |
| AR (1) | AR108301A1 (es) |
| AU (1) | AU2017252222B2 (es) |
| BR (1) | BR112018070677B1 (es) |
| CA (1) | CA3020378A1 (es) |
| CL (1) | CL2018002410A1 (es) |
| CO (1) | CO2018008759A2 (es) |
| CR (1) | CR20180499A (es) |
| CY (1) | CY1123186T1 (es) |
| DK (1) | DK3445767T3 (es) |
| DO (1) | DOP2018000222A (es) |
| EA (1) | EA036551B1 (es) |
| ES (1) | ES2791319T3 (es) |
| HR (1) | HRP20200673T1 (es) |
| HU (1) | HUE049591T2 (es) |
| IL (1) | IL262237B (es) |
| LT (1) | LT3445767T (es) |
| MA (1) | MA44721B1 (es) |
| ME (1) | ME03729B (es) |
| MX (1) | MX2018012711A (es) |
| NI (1) | NI201800093A (es) |
| PE (1) | PE20181803A1 (es) |
| PH (1) | PH12018502227A1 (es) |
| PL (1) | PL3445767T3 (es) |
| PT (1) | PT3445767T (es) |
| RS (1) | RS60257B1 (es) |
| SG (1) | SG11201805838UA (es) |
| SI (1) | SI3445767T1 (es) |
| SV (1) | SV2018005742A (es) |
| TN (1) | TN2018000319A1 (es) |
| TW (1) | TWI742074B (es) |
| WO (1) | WO2017182625A1 (es) |
| ZA (1) | ZA201807766B (es) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11066416B2 (en) | 2016-02-04 | 2021-07-20 | The Johns Hopkins University | Rapafucin derivative compounds and methods of use thereof |
| MX2018009408A (es) | 2016-02-04 | 2018-11-09 | Univ Johns Hopkins | Rapaglutinas, nuevos inhibidores de transportadores de glucosa (glut) y uso de los mismos. |
| CA3013650A1 (en) | 2016-02-04 | 2017-08-10 | The Johns Hopkins University | Rapadocins, inhibitors of equilibrative nucleoside transporter 1 and uses thereof |
| JP6894449B2 (ja) | 2016-04-22 | 2021-06-30 | アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ | 癌を治療するためのマクロ環状ｍｃｌ１阻害剤 |
| EP3458459B1 (en) | 2016-05-19 | 2022-04-27 | Bayer Aktiengesellschaft | Macrocyclic indole derivatives |
| TWI781996B (zh) * | 2017-03-31 | 2022-11-01 | 瑞典商阿斯特捷利康公司 | 合成ｍｃｌ-１抑制劑之方法 |
| TW201904976A (zh) * | 2017-03-31 | 2019-02-01 | 瑞典商阿斯特捷利康公司 | Ｍｃｌ-１抑制劑及其使用方法 |
| UA126586C2 (uk) | 2017-08-15 | 2022-11-02 | Еббві Інк. | Макроциклічні інгібітори mcl-1 та способи їх застосування |
| BR112020003163A2 (pt) * | 2017-08-15 | 2020-09-15 | AbbVie Deutschland GmbH & Co. KG | inibidores macrocíclicos de mcl-1 e métodos de uso |
| UY37971A (es) | 2017-11-17 | 2019-06-28 | Bayer Ag | Derivados de indol macrocíclicos sustituidos |
| US20210253598A1 (en) * | 2017-11-17 | 2021-08-19 | Bayer Aktiengesellschaft | Aryl annulated macrocyclic indole derivatives |
| EP3710449B1 (en) | 2017-11-17 | 2022-07-06 | The Broad Institute, Inc. | Macrocyclic fluorine substituted indole derivatives as mcl-1 inhibitors, for use in the treatment of cancer |
| WO2019096911A1 (en) | 2017-11-17 | 2019-05-23 | The Broad Institute, Inc. | Macrocyclic indole derivatives |
| AR113887A1 (es) | 2017-11-17 | 2020-06-24 | Bayer Ag | Derivados de indol macrocíclicos sustituidos con cloro |
| US11447504B2 (en) | 2017-11-17 | 2022-09-20 | Bayer Aktiengesellschaft | Macrocyclic chlorine substituted indole derivatives |
| TW202014184A (zh) * | 2018-04-30 | 2020-04-16 | 瑞典商阿斯特捷利康公司 | 用於治療癌症之組合 |
| WO2020063792A1 (zh) * | 2018-09-30 | 2020-04-02 | 江苏恒瑞医药股份有限公司 | 吲哚类大环衍生物、其制备方法及其在医药上的应用 |
| TWI810397B (zh) | 2018-11-14 | 2023-08-01 | 瑞典商阿斯特捷利康公司 | 治療癌症之方法 |
| CN111205309B (zh) * | 2018-11-21 | 2023-04-07 | 江苏恒瑞医药股份有限公司 | 吲哚类大环衍生物、其制备方法及其在医药上的应用 |
| TWI749404B (zh) * | 2018-11-22 | 2021-12-11 | 大陸商蘇州亞盛藥業有限公司 | 作為mcl-1抑制劑的大環吲哚 |
| TWI760685B (zh) * | 2019-01-23 | 2022-04-11 | 大陸商蘇州亞盛藥業有限公司 | 作為mcl-1抑制劑的大環稠合的吡唑 |
| EP3924358A4 (en) * | 2019-03-08 | 2023-07-05 | Zeno Management, Inc. | MACROCYCLIC COMPOUNDS |
| CN113574058B (zh) * | 2019-04-30 | 2024-04-16 | 江苏恒瑞医药股份有限公司 | 吲哚类大环衍生物、其制备方法及其在医药上的应用 |
| PE20220218A1 (es) | 2019-05-20 | 2022-02-02 | Novartis Ag | Conjugados de anticuerpo-farmaco inhibidores de mcl-1 y sus metodos de uso |
| WO2020254471A1 (en) | 2019-06-21 | 2020-12-24 | Janssen Pharmaceutica Nv | Macrocyclic inhibitors of mcl-1 |
| CN114096546A (zh) | 2019-07-09 | 2022-02-25 | 詹森药业有限公司 | 用作mcl-1抑制剂的大环螺环衍生物 |
| WO2021067405A1 (en) * | 2019-10-01 | 2021-04-08 | The Johns Hopkins University | Neuroprotective compounds and methods of use thereof |
| WO2021092053A1 (en) * | 2019-11-08 | 2021-05-14 | Unity Biotechnology, Inc. | Mcl-1 inhibitor macrocycle compounds for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer |
| WO2021092061A1 (en) * | 2019-11-08 | 2021-05-14 | Unity Biotechnology, Inc. | Combination treatment for senescence-associated diseases |
| AU2020388974A1 (en) | 2019-11-21 | 2022-07-07 | Janssen Pharmaceutica Nv | Macrocyclic sulfonyl derivatives as MCL-1 inhibitors |
| CA3157731A1 (en) | 2019-11-21 | 2021-05-27 | Frederik Jan Rita Rombouts | Macrocyclic indole derivatives as mcl-1 inhibitors |
| WO2021126316A1 (en) * | 2019-12-18 | 2021-06-24 | Zeno Management, Inc. | Macrocyclic compounds |
| CA3168355A1 (en) | 2020-02-21 | 2021-08-26 | Frederik Jan Rita Rombouts | Macrocyclic indole derivatives as inhibitors of mcl-1 |
| CN115335384A (zh) * | 2020-03-30 | 2022-11-11 | 江苏恒瑞医药股份有限公司 | 一种吲哚类大环衍生物的结晶形式及其制备方法 |
| US20230265105A1 (en) | 2020-05-29 | 2023-08-24 | Janssen Pharmaceutica Nv | Macrocyclic 7-pyrazol-5-yl-indole derivatives as inhibitors of mcl-1 |
| CA3181816A1 (en) | 2020-06-19 | 2021-12-23 | Aldo Peschiulli | N-linked macrocyclic 4-(pyrazol-5-yl)-indole derivatives as inhibitors of mcl-1 |
| AU2021291056A1 (en) | 2020-06-19 | 2023-02-23 | Janssen Pharmaceutica Nv | N-linked macrocyclic 7-(pyrazol-5-yl)-indole derivatives as inhibitors of MCL-1 |
| BR112023000212A2 (pt) | 2020-07-08 | 2023-01-31 | Janssen Pharmaceutica Nv | Éter macrocíclico contendo derivados de indol como inibidores de mcl-1 |
| WO2022032284A1 (en) * | 2020-08-07 | 2022-02-10 | Zeno Management, Inc. | Macrocyclic compounds |
| JP2023553808A (ja) | 2020-11-24 | 2023-12-26 | ノバルティス アーゲー | Ｍｃｌ－１阻害剤抗体－薬物コンジュゲートおよび使用方法 |
| EP4008324A1 (en) | 2020-12-07 | 2022-06-08 | Cellestia Biotech AG | Combinations comprising an inhibitor of an anti-apoptotic protein, such as bcl-2, bcl-xl, bclw or mcl-1, and a notch signaling pathway inhibitor for treating cancer |
| CN116710458A (zh) | 2020-12-17 | 2023-09-05 | 詹森药业有限公司 | 作为mcl-1抑制剂的支链大环4-(吡唑-5-基)-吲哚衍生物 |
| CA3206202A1 (en) | 2021-02-12 | 2022-08-18 | Janssen Pharmaceutica Nv | Macrocyclic 1,3-bridged 6-chloro-7-pyrazol-4-yl-1h-indole-2-carboxylate and 6-chloro-7-pyrimidin-5-yl-1h-indole-2-carboxylate derivatives as mcl-1 inhibitors for the treatment of cancer |
| WO2022251247A1 (en) * | 2021-05-28 | 2022-12-01 | Zeno Management, Inc. | Macrocyclic compounds |
| CA3222752A1 (en) | 2021-06-11 | 2022-12-15 | Gilead Sciences, Inc. | Combination mcl-1 inhibitors with anti-body drug conjugates |
| CA3222269A1 (en) | 2021-06-11 | 2022-12-15 | Gilead Sciences, Inc. | Combination mcl-1 inhibitors with anti-cancer agents |
| CN115490708A (zh) * | 2021-06-18 | 2022-12-20 | 苏州亚盛药业有限公司 | 磺酰胺类大环衍生物及其制备方法和用途 |
| WO2023057484A1 (en) | 2021-10-06 | 2023-04-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting and improving the efficacy of mcl-1 inhibitor therapy |
| WO2023225359A1 (en) | 2022-05-20 | 2023-11-23 | Novartis Ag | Antibody-drug conjugates of antineoplastic compounds and methods of use thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2134685B1 (en) | 2007-04-16 | 2015-09-02 | AbbVie Inc. | 7-nonsubstituted indole derivatives as mcl-1 inhibitors |
| KR101511074B1 (ko) * | 2007-04-16 | 2015-04-13 | 애브비 인코포레이티드 | 7-치환된 인돌 Ｍｃｌ-1 억제제 |
| PL2379580T3 (pl) * | 2008-12-22 | 2014-05-30 | Merck Sharp & Dohme | Nowe środki przeciwbakteryjne do leczenia zakażeń wywołanych bakteriami Gram-dodatnimi |
| WO2011079007A1 (en) * | 2009-12-23 | 2011-06-30 | Ironwood Pharmaceuticals, Inc. | Crth2 modulators |
| PT2710018T (pt) * | 2011-05-19 | 2022-03-01 | Fundacion Del Sector Publico Estatal Centro Nac De Investigaciones Oncologicas Carlos Iii F S P Cnio | Compostos macrocíclicos como inibidores de proteína quinases |
| US10093640B2 (en) | 2012-09-21 | 2018-10-09 | Vanderbilt University | Substituted benzofuran, benzothiophene and indole MCL-1 inhibitors |
| WO2015031608A1 (en) | 2013-08-28 | 2015-03-05 | Vanderbilt University | Substituted indole mcl-1 inhibitors |
| PT3105236T (pt) * | 2014-02-12 | 2017-12-22 | Viiv Healthcare Uk (No 5) Ltd | Macrociclos de benzotiazole como inibidores da replicação do vírus da imunodeficiência humana |
| CA2943815C (en) | 2014-03-27 | 2023-04-04 | Vanderbilt University | Substituted indole mcl-1 inhibitors |
| EP3129387B1 (en) * | 2014-04-11 | 2019-06-26 | Bayer Pharma Aktiengesellschaft | Novel macrocyclic compounds |
| US9949965B2 (en) | 2014-10-17 | 2018-04-24 | Vanderbilt University | Tricyclic indole Mcl-1 inhibitors and uses thereof |
| JP6894449B2 (ja) | 2016-04-22 | 2021-06-30 | アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ | 癌を治療するためのマクロ環状ｍｃｌ１阻害剤 |
-
2017
- 2017-04-21 JP JP2018553226A patent/JP6894449B2/ja active Active
- 2017-04-21 BR BR112018070677-9A patent/BR112018070677B1/pt active IP Right Grant
- 2017-04-21 CA CA3020378A patent/CA3020378A1/en active Pending
- 2017-04-21 SI SI201730246T patent/SI3445767T1/sl unknown
- 2017-04-21 KR KR1020187033540A patent/KR102388208B1/ko active IP Right Grant
- 2017-04-21 LT LTEP17720720.6T patent/LT3445767T/lt unknown
- 2017-04-21 RS RS20200549A patent/RS60257B1/sr unknown
- 2017-04-21 US US15/493,210 patent/US9840518B2/en active Active
- 2017-04-21 TN TNP/2018/000319A patent/TN2018000319A1/en unknown
- 2017-04-21 PL PL17720720T patent/PL3445767T3/pl unknown
- 2017-04-21 CO CONC2018/0008759A patent/CO2018008759A2/es unknown
- 2017-04-21 MA MA44721A patent/MA44721B1/fr unknown
- 2017-04-21 AR ARP170101026A patent/AR108301A1/es unknown
- 2017-04-21 CR CR20180499A patent/CR20180499A/es unknown
- 2017-04-21 HU HUE17720720A patent/HUE049591T2/hu unknown
- 2017-04-21 WO PCT/EP2017/059511 patent/WO2017182625A1/en active Application Filing
- 2017-04-21 ES ES17720720T patent/ES2791319T3/es active Active
- 2017-04-21 PT PT177207206T patent/PT3445767T/pt unknown
- 2017-04-21 TW TW106113380A patent/TWI742074B/zh active
- 2017-04-21 PE PE2018001558A patent/PE20181803A1/es unknown
- 2017-04-21 EA EA201892300A patent/EA036551B1/ru not_active IP Right Cessation
- 2017-04-21 CN CN201780022366.0A patent/CN109071566B/zh active Active
- 2017-04-21 SG SG11201805838UA patent/SG11201805838UA/en unknown
- 2017-04-21 ME MEP-2020-99A patent/ME03729B/me unknown
- 2017-04-21 DK DK17720720.6T patent/DK3445767T3/da active
- 2017-04-21 AU AU2017252222A patent/AU2017252222B2/en active Active
- 2017-04-21 MX MX2018012711A patent/MX2018012711A/es unknown
- 2017-04-21 EP EP17720720.6A patent/EP3445767B1/en active Active
- 2017-10-23 US US15/790,660 patent/US10196404B2/en active Active
-
2018
- 2018-08-23 CL CL2018002410A patent/CL2018002410A1/es unknown
- 2018-09-12 SV SV2018005742A patent/SV2018005742A/es unknown
- 2018-09-25 NI NI201800093A patent/NI201800093A/es unknown
- 2018-10-05 DO DO2018000222A patent/DOP2018000222A/es unknown
- 2018-10-09 IL IL262237A patent/IL262237B/en unknown
- 2018-10-18 PH PH12018502227A patent/PH12018502227A1/en unknown
- 2018-11-19 ZA ZA2018/07766A patent/ZA201807766B/en unknown
- 2018-12-18 US US16/223,538 patent/US10889594B2/en active Active
-
2020
- 2020-04-28 HR HRP20200673TT patent/HRP20200673T1/hr unknown
- 2020-05-14 CY CY20201100443T patent/CY1123186T1/el unknown
- 2020-12-04 US US17/111,896 patent/US11472816B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NI201800093A (es) | Inhibidores de mcl1 macrocíclicos para tratar el cáncer | |
| ECSP19052302A (es) | Derivados de benzooxazol como inmunomoduladores | |
| ECSP18094790A (es) | Piridinas sustituidas con heteroarilo y métodos de uso referencia cruzada a solicitudes relacionadas | |
| CO2019003482A2 (es) | Compuestos derivados de ciclobutano o azetidina 1,3 disustituidos como inhibidores de la prostaglandina d sintasa hematopoyética | |
| BR112017003658A2 (pt) | composto, mistura, métodos para tratamento de uma doença e para inibição de uma glicosidase, e, composição farmacêutica. | |
| NI201600165A (es) | Inhibidores de desmetilasa 1 específica a lisina | |
| NI201700056A (es) | 2-amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de bace1 para el tratamiento de la enfermedad de alzhéimer | |
| ECSP16072941A (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
| PE20150887A1 (es) | Compuestos de benceno sustituidos | |
| CO2018000589A2 (es) | Oxiesteroles y composiciones farmacéuticas que los contienen | |
| UY35617A (es) | Inhibidores de la fosfatidilinositol 3-quinasa | |
| DOP2017000278A (es) | Piridinas sustituidas y método de uso | |
| NZ726608A (en) | Phosphatidylinositol 3-kinase inhibitors | |
| NZ726360A (en) | Phosphatidylinositol 3-kinase inhibitors | |
| DOP2021000077A (es) | Derivados de quinolina como inhibidores de la integrina alfa4beta7 | |
| MX2018015302A (es) | Esteres de acidos grasos de cadena media de beta-hidroxibutirato y butanodiol y composiciones y metodos para usar los mismos. | |
| BR112018008506B8 (pt) | Compostos inibidores do fator xia, composição farmacêutica e usos dos mesmos | |
| EA201792425A1 (ru) | Трициклические соединения и их применение в качестве ингибиторов фосфодиэстераз | |
| PH12019501529A1 (en) | Poly-adp ribose polymerase (parp) inhibitors | |
| AR105400A1 (es) | Inhibidores de jak1 | |
| SV2016005317A (es) | Derivados de pirrolidina -2,5-diona, composiciones farmacéuticas y métodos para usar como inhibidores ido1 | |
| BR112017006998A2 (pt) | compostos de aminopurina substituídos, composições dos mesmos e métodos de tratamento com os mesmos |